Incyte Co. (NASDAQ:INCY) Stock Holdings Lifted by Horizon Investments LLC

Horizon Investments LLC raised its position in Incyte Co. (NASDAQ:INCY) by 9.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,376 shares of the biopharmaceutical company’s stock after purchasing an additional 206 shares during the quarter. Horizon Investments LLC’s holdings in Incyte were worth $164,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in INCY. Quintet Private Bank Europe S.A. bought a new stake in shares of Incyte during the 4th quarter worth about $26,000. Global X Japan Co. Ltd. boosted its stake in shares of Incyte by 144.7% during the 4th quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 230 shares in the last quarter. Brooklyn Investment Group bought a new stake in shares of Incyte during the 3rd quarter worth about $30,000. R Squared Ltd bought a new stake in shares of Incyte during the 4th quarter worth about $30,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Incyte during the 3rd quarter worth about $33,000. Institutional investors own 96.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on INCY shares. StockNews.com downgraded Incyte from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 12th. Guggenheim cut Incyte from a “buy” rating to a “neutral” rating and set a $92.00 price objective for the company. in a research report on Tuesday. Citigroup cut their price objective on Incyte from $97.00 to $88.00 and set a “buy” rating for the company in a research report on Tuesday, February 11th. Truist Financial cut their price objective on Incyte from $74.00 to $72.00 and set a “hold” rating for the company in a research report on Tuesday. Finally, Stifel Nicolaus boosted their price objective on Incyte from $75.00 to $77.00 and gave the stock a “hold” rating in a research report on Monday, February 10th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $75.13.

Insider Transactions at Incyte

In related news, EVP Steven H. Stein sold 12,352 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $72.69, for a total transaction of $897,866.88. Following the sale, the executive vice president now owns 66,967 shares of the company’s stock, valued at approximately $4,867,831.23. This trade represents a 15.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Barry P. Flannelly sold 19,807 shares of the firm’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $67.69, for a total value of $1,340,735.83. Following the sale, the executive vice president now directly owns 33,567 shares in the company, valued at $2,272,150.23. The trade was a 37.11 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 46,827 shares of company stock valued at $3,322,618. Corporate insiders own 17.60% of the company’s stock.

Incyte Trading Up 0.4 %

Shares of INCY opened at $60.58 on Friday. Incyte Co. has a 1 year low of $50.35 and a 1 year high of $83.95. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01. The stock has a 50 day simple moving average of $70.78 and a 200-day simple moving average of $70.13. The stock has a market cap of $11.72 billion, a PE ratio of 224.38, a PEG ratio of 0.41 and a beta of 0.76.

Incyte (NASDAQ:INCY) last issued its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%. On average, sell-side analysts predict that Incyte Co. will post 4.86 EPS for the current fiscal year.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.